- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | MABWELL-B (02493): DATE OF BOARD MEETING | - | HKEx | ||
| 03.08. | MABWELL-B 9MW5211 Injection Clinical Trial Application Approved by NMPA | 1 | AASTOCKS | ||
| 31.07. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | - | HKEx | ||
| 15.07. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | - | HKEx | ||
| 07.07. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | - | HKEx | ||
| 24.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | - | HKEx | ||
| 23.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE RECEIPT OF NMPA APPROVAL FOR THE CLINICAL TRIAL APPLICATION OF 6MW5311 FOR INJECTION | - | HKEx | ||
| 18.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE ORAL AND POSTER PRESENTATIONS OF THE LATEST CLINICAL DATA OF 9MW2821 AT THE 2026 ESMO CONGRESS ... | 1 | HKEx | ||
| MABWELL SHANGHAI BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 18.06. | MABWELL-B (02493): APPOINTMENT OF MEMBERS OF SENIOR MANAGEMENT | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): CHANGE OF AUTHORISED REPRESENTATIVE | - | HKEx | ||
| 18.06. | MABWELL-B (02493): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR | - | HKEx | ||
| 18.06. | MABWELL-B (02493): RETIREMENT OF DIRECTORS ELECTION OF THE THIRD SESSION OF THE BOARD OF DIRECTORS ELECTION OF CHAIRMAN OF THE THIRD SESSION OF THE BOARD ... | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): POLL RESULTS OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 12.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE RECEIPT OF FDA CLEARANCE FOR THE CLINICAL TRIAL APPLICATION OF 6MW5311 FOR INJECTION | - | HKEx | ||
| 04.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | 3 | HKEx | ||
| 01.06. | MABWELL-B (02493): POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 29.05. | MABWELL-B (02493): REMUNERATION MANAGEMENT SYSTEM FOR DIRECTORS AND SENIOR MANAGEMENT | - | HKEx | ||
| 29.05. | MABWELL-B (02493): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 29.05. | MABWELL-B (02493): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,750 | +1,10 % | Qiagen: Jonathan Pratt übernimmt den Vorstandsvorsitz | Qiagen bekommt zum 1. September 2026 einen neuen Vorstandschef. Jonathan M. Pratt übernimmt den Posten von Thierry Bernard, der als CEO und Geschäftsführer zurücktritt und den Übergang noch bis zum... ► Artikel lesen | |
| CELULARITY | 2,070 | +140,70 % | Celularity Inc.: Celularity Provides Update Regarding Nasdaq Listing Compliance | FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the "Company") today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,580 | -6,08 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| ERASCA | 19,430 | +1,52 % | Erasca, Inc. - 8-K, Current Report | ||
| PROPANC BIOPHARMA | 2,330 | +117,76 % | Propanc Biopharma, Inc.: Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit | MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,97 | +0,02 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,270 | +0,28 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| MODERNA | 119,60 | -6,90 % | BioNTech Aktie: Moderna-Erfolg entfacht neue Krebsimpfstoff-Fantasie | Die BioNTech Aktie hat am Mittwoch kräftig von den positiven Nachrichten des US-Konkurrenten Moderna profitiert. Der Aktienkurs des Mainzer Biotech-Unternehmens sprang an der NASDAQ auf Schlusskursbasis... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,170 | +1,23 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,400 | -0,31 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 120,70 | -3,81 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BIONTECH | 95,55 | -1,09 % | Noerr berät DUBAG beim Erwerb von JPT Peptide Technologies von BioNTech | ||
| AMYLYX PHARMACEUTICALS | 37,540 | +1,30 % | Guggenheim raises Amylyx stock price target on financing, trial data | ||
| ENLIVEN THERAPEUTICS | 60,58 | -0,38 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,325 | -0,69 % | H.C. Wainwright raises Relay Therapeutics price target to $29 |
MABWELL SHANGHAI BIOSCIENCE CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MABWELL SHANGHAI BIOSCIENCE CO LTD finden Sie auf Wallstreet Online.